SCHEMBL1066552

SCHEMBL1066552

O=C(NN(C(=O)O)c1ccc(-c2cccs2)cc1)c1ccc(Br)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.52
BCR P11274 1/20 0.52
ADCY1 Q08828 1/20 0.45
HPGDS O60760 1/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
TDP1 Q9NUW8 2/20 0.42
MAPT P10636 1/20 0.42
THRB P10828 1/20 0.42
HDAC1 Q13547 5/20 0.41
HDAC2 Q92769 2/20 0.41
HDAC3 O15379 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MCHR1 Q99705 1/20 0.39
DRD2 P14416 3/20 0.39
DRD4 P21917 3/20 0.39
HTR2A P28223 1/20 0.39
ERO1A Q96HE7 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4794017 0.86 HDAC2 (0.44) ABL1BCRHPGDSMEN1KMT2A
SCHEMBL4669170 0.86 HDAC1 (0.48) HPGDSHDAC1DRD2DRD4HTR2A
SCHEMBL4579392 0.85 HPGDS (0.46) HPGDSHDAC1DRD2DRD4HTR2A
SCHEMBL4580709 0.81 TDP1 (0.51) HPGDSMEN1KMT2ATDP1MAPT
SCHEMBL4579334 0.79 HPGDS (0.40) HPGDSMEN1KMT2AHDAC1HDAC2
SCHEMBL1068512 0.78 ABL1 (0.54) ABL1BCRMEN1KMT2ATDP1
SCHEMBL4578392 0.77 MCHR1 (0.73) HDAC1MCHR1DRD2DRD4HTR2A
SCHEMBL1067900 0.76 CHRM4 (0.55) MAPTHDAC1HDAC2HDAC3L3MBTL1
SCHEMBL4581688 0.76 CREBBP (0.42) ABL1BCRHPGDSTDP1HDAC1
SCHEMBL4579575 0.75 DRD4 (0.59) HDAC1MCHR1DRD2DRD4HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7868205-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2011-01-11 US disclosed
US-20080132459-A1 Inhibitors of Histone Deacetylase METHYLGENE, INC. (CA) 2008-06-05 US disclosed
EP-1663953-A1 INHIBITORS OF HISTONE DEACETYLASE Methylgene, Inc. (CA) 2006-06-07 EP disclosed
WO-2005030705-A9 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC (CA) 2006-04-20 WO disclosed
WO-2005030705-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE, INC. (CA) 2005-04-07 WO disclosed
WO-2005030704-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE, INC. (CA) 2005-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132459-A1 Inhibitors of Histone Deacetylase HDAC1, HDAC5, HDAC3 ABL1 1873/4885BCR 2702/4885ADCY1 2948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.